What Matters Now
CME
Optimizing Treatment Selection in Chronic Lymphocytic Leukemia
Joshua Brody, MD, Mount Sinai
Graham Wehmeyer, MD, Icahn School of Medicine at Mount Sinai
88% of Peers Changed Their Practice After this Clinical Scenario
CME
A fit patient with IGHV-mutated CLL prefers treatment-free interval but has three defensible guideline-concordant frontline options with different duration, monitoring, and infusion profiles.
What Matters Now
CME
Optimizing Treatment Selection in Chronic Lymphocytic Leukemia
Joshua Brody, MD, Mount Sinai
Graham Wehmeyer, MD, Icahn School of Medicine at Mount Sinai
Corresponding Scenario
More Than One Right Answer - Choosing a Frontline Strategy When Continuous and Fixed-Duration Both Fit
See experiences from 55 peers
A fit patient with IGHV-mutated CLL prefers treatment-free interval but has three defensible guideline-concordant frontline options with different duration, monitoring, and infusion profiles.
How clinicians responded after this Clinical Scenario
78
%
begin unsure how to apply evidence
88
%
will implement a practice change
